Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M275,685Revenue $M74,331Net Margin (%)22.0Z-Score5.2
Enterprise Value $M261,357EPS $5.7Operating Margin %28.2F-Score7
P/E(ttm))17.6Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yY
Price/Book4.010-y EBITDA Growth Rate %4.3Quick Ratio2.0Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %3.5Current Ratio2.4Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %24.9ROA % (ttm)12.3Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)21.8Less Shares Outstanding y-yY
Payout Ratio %48.0Shares Outstanding M2,780ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJJohn Hussman 2014-12-31 Add1.19%$96.78 - $109.07
($105.37)
$ 99.15-6%Add 8301.89%111,325
JNJJoel Greenblatt 2014-12-31 Add0.66%$96.78 - $109.07
($105.43)
$ 99.15-6%Add 5420.84%790,529
JNJRobert Olstein 2014-12-31 Reduce-0.17%$96.78 - $109.07
($105.37)
$ 99.15-6%Reduce -14.46%71,000
JNJRichard Perry 2014-12-31 Reduce-0.11%$96.78 - $109.07
($105.37)
$ 99.15-6%Reduce -8.67%312,610
JNJJohn Rogers 2014-12-31 Add0.11%$96.78 - $109.07
($105.37)
$ 99.15-6%Add 17.80%632,132
JNJRay Dalio 2014-12-31 Reduce-0.02%$96.78 - $109.07
($105.37)
$ 99.15-6%Reduce -23.64%64,293
JNJHOTCHKIS & WILEY 2014-12-31 Sold Out $96.78 - $109.07
($105.37)
$ 99.15-6%Sold Out0
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 99.15-5%Reduce -99.80%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 99.15-5%Reduce -10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 99.15-5%Reduce -6.06%3,100,000
JNJDonald Yacktman 2014-09-30 Reduce-0.17%$99.82 - $108.64
($103.64)
$ 99.15-5%Reduce -4.36%8,651,258
JNJYacktman Fund 2014-09-30 Reduce-0.13%$99.82 - $108.64
($103.64)
$ 99.15-5%Reduce -3.70%3,900,000
JNJGeorge Soros 2014-09-30 Sold Out -0.04%$99.82 - $108.64
($103.64)
$ 99.15-5%Sold Out0
JNJJoel Greenblatt 2014-09-30 Buy 0.02%$99.82 - $108.64
($103.64)
$ 99.15-5%New holding14,319
JNJRay Dalio 2014-09-30 Add0.02%$99.82 - $108.64
($103.64)
$ 99.15-5%Add 27.77%84,193
JNJDodge & Cox 2014-09-30 Add$99.82 - $108.64
($103.64)
$ 99.15-5%Add 21.93%47,095
JNJHOTCHKIS & WILEY 2014-06-30 Reduce-0.89%$96.54 - $105.76
($101.02)
$ 99.15-2%Reduce -63.73%1,426,614
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 99.15-2%Reduce -13.16%3,300,000
JNJRobert Olstein 2014-06-30 Reduce-0.31%$96.54 - $105.76
($101.02)
$ 99.15-2%Reduce -20.91%87,000
JNJDonald Yacktman 2014-06-30 Reduce-0.21%$96.54 - $105.76
($101.02)
$ 99.15-2%Reduce -5.50%9,045,902
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fasolo PeterVP, Global Human Resources 2015-03-05Sell115,307$102.4-2.21view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-7.75view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-6.79view
CULLEN JAMESDirector 2014-09-10Sell2,446$104.12-3.82view
Caruso Dominic JVP, Finance; CFO 2014-08-21Sell30,000$104.3-3.99view
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.050.09view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.157.5view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.399.57view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.686.9view
Stoffels PaulusChief Scientific Officer 2013-07-25Sell45,440$92.48.38view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    These 10 Stocks Swim In Cash Mar 17 2015 
    7 Stocks With A Strong Cash To Dividend Coverage Mar 17 2015 
    Analyzing Joel Greenblatt's Top Buys: Johnson & Johnson Mar 17 2015 
    Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
    Optimizing Your Asset Allocation Mar 10 2015 
    AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Berkshire Hathaway The All Season Stock Mar 03 2015 
    Dividend Growth Stocks Are My Conviction Mar 03 2015 
    Investing: Keep It Simple – Part 2 Feb 26 2015 


    More From Other Websites
    MedTech M&As Continue Regardless of Tax Scenarios - Industry Outlook Mar 26 2015
    Pressure's On Senate To Pass 'Doc Fix' In Latest Blow To Fee-For-Service Medicine Mar 26 2015
    Zacks Industry Outlook Highlights: Johnson & Johnson and Medtronic - Press Releases Mar 26 2015
    Cramer: Nasdaq's griddle too hot Mar 25 2015
    Kraft a Menu at the Buffett Buffet With Warren’s Latest Deal Mar 25 2015
    Kraft a Menu at the Buffett Buffet With Warren's Latest Deal Mar 25 2015
    Can Pharma Conquer The Consumer The Way Apple Did? This App Might Help Mar 25 2015
    From Snitch Pill to Xbox Sensors, Novartis Goes Digital Mar 25 2015
    Six Standout Startups From This Year's Y Combinator Demo Days Mar 25 2015
    The Pharmacyclics–AbbVie Merger: The Basics of Pharmacyclics Mar 25 2015
    Great Stocks That Cost Less Than $10 Mar 25 2015
    From Pills That Snitch to Xbox Sensors, Drugmaker Goes High Tech Mar 24 2015
    Why PETA Is Now a Domino's and Shake Shack Shareholder Mar 24 2015
    Johnson & Johnson May See EPS Drag Through 2018 Mar 24 2015
    Stocks to Cure What Ails on World TB Day - Analyst Blog Mar 24 2015
    AstraZeneca to Disclose Trial Data, but how Independent is its Review Panel? Mar 24 2015
    Could the Pharmacyclics–AbbVie Merger Get Competitive? Mar 24 2015
    The Expansion of Internet Domains Would Go Better At A Slower Pace Mar 24 2015
    New Alzheimer's Research Throws Cold Water on Biogen's Recent Breakthrough Mar 23 2015
    Pharmacyclics chief to receive $3.6bn from takeover Mar 23 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK